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Protocol
AbstrACt
Introduction People with rheumatoid arthritis (RA) 
frequently report reduced health-related quality of 
life (HRQoL), the impact one’s health has on physical, 
emotional and social well-being. There are likely 
numerous causes for poor HRQoL, but people with RA 
have identified sleep disturbances as a key contributor 
to their well-being. This study will identify sleep/wake 
rhythm-associated parameters that predict HRQoL in 
patients with RA.
Methods and analysis This prospective cohort study 
will recruit 350 people with RA, aged 18 years or 
older. Following completion of a paper-based baseline 
questionnaire, participants will record data on 10 
symptoms including pain, fatigue and mood two times a 
day for 30 days using a study-specific mobile application 
(app). A triaxial accelerometer will continuously record 
daytime activity and estimate evening sleep parameters 
over the 30 days. Every 10 days following study initiation, 
participants will complete a questionnaire that measures 
disease specific (Arthritis Impact Measurement Scale 
2-Short Form (AIMS2-SF)) and generic (WHOQOL-BREF) 
quality of life. A final questionnaire will be completed at 
60 days after entering the study. The primary outcomes 
are the AIMS2-SF and WHOQOL-BREF. Structural equation 
modelling and latent trajectory models will be used to 
examine the relationship between sleep/wake rhythm-
associated parameters and HRQoL, over time.
Ethics and dissemination Results from this study will be 
disseminated at regional and international conferences, in 
peer-reviewed journals and Patient and Public Engagement 
events, as appropriate.
IntroduCtIon 
Quality of life, sleep and rheumatoid arthritis 
(QUASAR) is a prospective cohort study 
which will use a patient-designed smart-
phone/tablet app and accelerometer to 
collect information on sleep and health-re-
lated quality of life (HRQoL) in rheumatoid 
arthritis (RA).
RA is a common chronic inflammatory 
disease characterised by joint damage, pain 
and disability.1 The occurrence of RA is 
between two and four times greater in women 
and as many as 70% of men and women of 
working age with RA stop work within 10–15 
years of disease duration due to the condi-
tion.2 3 People with RA frequently report 
reduced HRQoL, which can be characterised 
strengths and limitations of this study
 ► This study will take advantage of advances in mobile 
health to embed data collection into the daily lives 
of participants.
 ► Using a patient codesigned smartphone/tablet app, 
it will capture objective and subjective sleep as well 
as self-reported symptoms.
 ► Sophisticated structural equation modelling and 
latent trajectory models will enable the study to 
disentangle the complex relationship between sleep, 
health-related quality of life (HRQoL) and other 
symptoms.
 ► While the use of actigraphy allows the collection 
of objective sleep data, it is not able to inform 
investigation of the relationship between HRQoL and 
sleep architectural parameters or sleep oscillations 
(eg, spindles, slow waves).
 ► Potential sources of bias include (1) sampling 
bias, if those recruited to this study are only those 
who experience sleep disturbances and/or are 
comfortable/familiar with using smartphone apps 
and activity monitors and (2) loss to follow-up bias 
if those who do not complete the full data collection 
protocol are systematically different from those who 
do.
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as the impact one’s health has on physical, emotional and 
social well-being. People with RA have poorer HRQoL 
when compared with those with other rheumatic diseases4 
or healthy peers.5 6 Poor HRQoL may even persist when 
the disease is well controlled.5
Although there are likely numerous causes for poor 
HRQoL, people with RA have identified sleep distur-
bances as a key contributor to their well-being.7–9 It 
is well known that people with RA report substantial 
sleep disturbances,10 11 such as less total sleeping time 
and unrefreshing sleep8 and greater night time awak-
enings.7 9 The cyclical nature of relationships between 
sleep disruptions and symptoms such as pain, fatigue and 
disability is relatively well characterised and likely cycli-
cal.12–14However, few studies have determined the rela-
tionship between sleep and quality of life (QoL) among 
RA populations.
Studies which have investigated the relationship 
between sleep and HRQoL have tended to suggest that 
sleep problems are associated with poor HRQoL.15–18 
However, these studies have been of low quality and 
have been hampered by a number of methodolog-
ical challenges, which preclude accurate assessment 
and understanding of the relationship between sleep 
and HRQoL. First and foremost, sleep is a multifac-
eted behaviour which comprises objective and subjec-
tive components.19 Despite guidelines endorsing the 
measurement of both and the potential for discrepancy 
between subjective and objective reports,20 it is only 
subjective sleep which has been commonly measured 
within epidemiological studies because, historically, it 
has been difficult to objectively measure sleep outside 
of artificial laboratory settings. Studies have also tended 
to be cross-sectional in design or to have used low-res-
olution longitudinal data collection protocols which 
have not been able to collect data regarding the recur-
rent and fluctuating day-to-day changes in sleep and 
associated symptoms.
Now, advances in the availability of smartphone apps 
and wearables for health monitoring provide a hitherto 
unobtainable mechanism to collect regular self-reported 
symptoms and objective sleep data, while embedding data 
collection into participants’ everyday lives. This study will 
use a combination of patient codesigned smartphone/
tablet app (provided by uMotif, London, UK) and a 
triaxial accelerometer MotionWatch8 (MW8; CamNtech, 
Cambridge, UK) to capture both subjective and objec-
tive assessments of sleep quality, continuity and dura-
tion as well as the timing and stability of the periods of 
time when someone is asleep or active.21 Furthermore, 
the uMotif app will be used to collect information about 
self-reported symptoms which were identified as priorities 
by patients in a series of focus groups and patient involve-
ment activities. In doing so, this study aims to identify 
the relationship between sleep parameters, aspects of the 
sleep/wake rhythm-associated parameters and HRQoL in 
people with RA.
study objectives
1. Describe baseline and period distribution of sleep/
wake rhythm-associated parameters stratified by age, 
sex, socioeconomic status and disease characteristics.
2. Determine relative contributions of sleep/wake 
rhythm-associated parameters, pain, fatigue and 
mood to RA-HRQoL.
3. In an exploratory analysis to examine whether the 
relationship between disease severity, sleep/wake 
rhythm-associated parameters, pain, fatigue, mood 
and RA-HRQoL are moderated by age and sex.
4. Estimate the potential effect on RA-HRQoL of a suc-
cessful intervention targeted at the key identified 
pathway(s).
ExpErIMEntAl dEsIgn And MEthods: MEthods And 
AnAlysIs
study design
We will conduct a prospective cohort study to investigate 
the relationships between sleep and HRQoL in people 
with RA.
Identifying and recruiting potential participants
Participants will be recruited via three channels. The 
primary source for participants will be the National Rheu-
matoid Arthritis Society (NRAS). NRAS is a national 
patient organisation with over 7000 members. Emails 
advertising the study will be sent to NRAS mailing list 
members and will include a copy of the study information 
pack comprising:
1. Study poster
2. Participant information sheet
3. Copy of the consent form (for information only)
4. A link to complete an online screening questionnaire
Following approval from the Health Research Authority 
and via arrangements with Clinical Commissioning 
Groups, participants will also be recruited via NHS 
mailing lists, where such mailing lists are available. NHS 
mailing lists provide the opportunity to search general 
practitioner (GP) records for potentially eligible partici-
pants. Local Clinical Research Network (CRN) teams will 
search GP records for patients aged 18 or older, with a 
diagnosis of RA and who are in receipt of a disease modi-
fying antirheumatic drug (DMARD), as recommended by 
Muller et al.22 Letters will be sent to the identified patients, 
provided the GP or clinical team in the practice confirms 
that approaching the patient is acceptable. Reasons for 
not approaching patients may include previous refusal for 
records to be used for research, current hospitalisation or 
belief that the participant is not capable of participation. 
Within the letter, participants will be briefly introduced to 
the study and persons interested in participating will be 
asked to email the study team directly for the study infor-
mation pack, the contents of which are detailed above.
Information about the study will be displayed on the 
NIHR CRN Portfolio to encourage NHS sites to support 
study recruitment by displaying posters advertising the 
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study in any NHS Rheumatology clinics. NHS sites inter-
ested in supporting the study will contact the study team 
directly for further information and all relevant docu-
mentation needed to confirm they have the capacity and 
capability required to support the study. The displayed 
posters will provide brief information about the study and 
will ask persons interested in participating to email the 
study team directly for the study information pack, the 
contents of which are detailed above.
Following the receipt of the study information pack, 
potential participants follow an identical recruitment 
strategy (figure 1).
Screening questionnaire
Persons who receive the study information pack and are 
interested in participating in the study will be asked to 
complete the study screening questionnaire. Potential 
participants are asked to record their sex and date of 
birth and to confirm whether they (1) have a diagnosis of 
RA (including date of diagnosis), (2) are currently using 
DMARDs (biological or conventional synthetic), (3) have 
access to an Android or Apple smartphone or tablet. For 
the purposes of exclusion criteria, interested persons 
must also indicate whether they are currently employed 
in shift work. Finally, potential participants will be asked 
to give consent and contact details and preferred contact 
time (09:00  to 12:00 hours, 12:00 to 15:00 hours, 15:00 to 
18:00 hours or 18:00 to 20:00 hours) to enable the study 
team to contact them to discuss participation in the study.
Eligibility criteria
Screening questionnaire respondents will be considered 
eligible for the study if they:
 ► are aged ≥18 years,
 ► have a diagnosis of RA,
 ► are currently using DMARDs (biological or conven-
tional synthetic),
 ► have access to an Android or Apple smartphone or 
tablet.
Respondents would be excluded from the study if they:
 ► are currently employed in a job that requires shift 
work.
QUASARid
Study participants will be asked to provide data via three 
different platforms: paper-based questionnaires, a study 
app (downloaded onto a smartphone or tablet) and a 
triaxial accelerometer that will measure daytime phys-
ical activity and sleep. To ensure that the data collected 
across these platforms can be consistently and accurately 
linked and matched to each participant, a unique partici-
pant identifier will be generated for each participant. The 
unique identifier, known as a QUASARid, will be auto-
matically generated as the unique survey response which 
is allocated to the participant when they commence the 
screening questionnaire.
Telephone call
Potential participants meeting the study inclusion 
criteria will be telephoned by a member of the study 
team. To ensure they have had adequate time to review 
the participant information sheet provided in the 
study information email, telephone calls will take place 
no earlier than 24 hours after receipt of a completed 
screening questionnaire. A total of four attempts to 
contact the potential participant will be made on 
consecutive week days. During the phone call, a verbal 
summary of the information sheet will be discussed 
Figure 1 Flow of participant entry into the study. QUASAR, quality of life, sleep and rheumatoid arthritis. 
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with the potential participant and they will be given the 
opportunity to ask as many questions about the study as 
they wish.
Verbal consent and agreement of study start date
Following the verbal summary of the study informa-
tion sheet, participants will be given the option to enrol 
into the study, delay participation, request more time to 
think about participation or decline to take part in the 
study. Written consent will subsequently be obtained 
by the completion of two paper copies of the consent 
form sent to participants within the study pack. The 
provided consent forms will be signed and dated by the 
team member responsible for recruitment at the point 
of obtaining verbal consent, with participants asked to 
complete their own signature at the time of completing 
the baseline questionnaire. One copy of the consent form 
will be returned by the participant at the end of their 
first 30 days in QUASAR, along with the actigraph watch 
and baseline questionnaire. The second copy is for the 
patients’ personal records.
Once verbal consent has been obtained, participants 
will be asked to agree to a study start date, which should be 
within 14 days of the telephone call taking place. Partici-
pants who are unable to commence the study within 14 
days will be asked to delay entry into the study. Those 
who agree a study start date will be asked to confirm their 
preferred postal address to which the study packs will be 
sent and a mobile phone number. The mobile phone 
number will be used to send participants text messages 
on the agreed study start date and throughout the study 
to encourage data completion and study compliance.
Study pack
The provision of verbal consent also enables the study 
pack to be prepared and posted to participants in advance 
of the agreed study start date. The study pack will include 
a letter of introduction, two copies of the consent form 
and a paper copy of the baseline questionnaire. Partici-
pants will also be provided with instructions to download 
and use the study app as well as an actigraph watch, called 
a MW8 (CamNtech) and associated instructions. The 
study pack will be sent from the University of Manchester 
using Special Delivery Guaranteed to arrive no less than 
1 day prior to the study start date.
Document completion—Consent form and baseline questionnaire
Participants are requested to complete paper copies of 
the consent form and baseline questionnaire (sent within 
the study pack) on or before the first day of symptom 
monitoring. Initially, the baseline questionnaire was 
incorporated into the study app to be completed as part 
of the onboarding process. However, due to limits on the 
number of questions which could be displayed per screen 
and the associated time required for data completion, 
app testing with the study team and members of a focus 
group indicated that this method of delivery would be less 
acceptable to participants than a paper-based document.
The participant’s QUASARid will be written onto both 
the consent form and covering page of the baseline ques-
tionnaire to enable data linkage between these docu-
ments, the study app and actigraph watch. To encourage 
completion of the questionnaire in advance of the moni-
toring period, participants will be asked to indicate the 
date on which they have completed the questionnaire on 
the covering page. They will return the baseline question-
naire along with the monitor at the end of the study.
The baseline questionnaire will comprise three sections: 
demographic information, information about RA and 
health status information.
demographics
Participants will record a number of demographic vari-
ables: sex, date of birth, weight and height, ethnicity, 
age left education, average weekly alcohol consumption, 
smoking status, occupational status, marital status and 
postcode. Participants will also indicate how likely they 
believe it is that sleep affects their QoL and the impact 
that RA has on their work productivity. A description of 
the reporting of these items is shown in table 1.
Information about rA
Disease activity
Participants will record the month and year of their diag-
nosis. Disease activity will be assessed using the Routine 
Assessment of Patient Index Data 3 (RAPID-3). The 
15-item RAPID-3 is free to use and has been validated 
in RA populations. The measure has good validity and 
acceptable reliability and responsiveness.23
The RAPID-3 measures three domains: physical function 
(13 discrete response items), pain (1-item 0–10 numerical 
rating scale (NRS)) and global health (1-item 0–10 NRS)) 
in the past week. The first 10 items of the physical func-
tion domain are scored, transformed into a 0.3–10 scale 
and summed with the pain and global health domains to 
produce an overall score of 0–30. These overall scores are 
then converted into a weighed RAPID-3 score and catego-
rised within the following disease activity score categories: 
near remission (0.3–1.0), low severity (1.3–2.0), moderate 
severity (2.3–4.0), high severity (4.3–10).
Comorbid rheumatic disease(s) and sleep-related problem(s) and 
menopausal status
Participants will be asked to record the presence of a 
variety of other rheumatic diseases, comorbidities which 
may affect sleep (eg, Sjögren’s syndrome, diabetes, 
multiple sclerosis, hypertension (table 1)) and meno-
pausal status.
For pragmatic reasons, it was not possible to embed 
specific questionnaires about the presence, severity or 
impact of sleep disorders, as it was necessary to balance 
the availability of data with minimal participant burden 
of data completion. Nevertheless, because the presence 
of such disorders represent important covariates which 
should be adjusted for within data analysis, participants 
will be asked to record whether they experience restless 
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leg syndrome and obstructive sleep apnoea/snoring. A 
full list of comorbidities collected is shown in table 1.
Insomnia is recorded using the Sleep Condition Indi-
cator (SCI), an 8-item questionnaire which has good 
concurrent validity, high internal consistency and is 
sensitive to change.24 The SCI performs well to detect 
possible insomnia disorder and is the only validated and 
widely used insomnia measure that indexes insomnia 
disorder against contemporary criteria (eg, Interna-
tional Classification of Sleep Disorders (ICSD-3); The 
Diagnostic and Statistical Manual of Mental Disorders 
(DSM-5)).24
Table 1 Baseline questionnaire domains and scales
Domain Scales/measurement
Demographics
Sex Tick box—male or female
Date of birth Day, month, year
Height and weight Free text (metric or imperial)
Ethnicity Free text
Age left education Free text
Smoking status Tick box—current, ex-smoker or never smoker
Occupational status Tick box—working full time, working part time, student, medically retired, voluntary 
worker, unemployed but seeking work or retired
Marital status Tick box—single, in a relationship, cohabiting, married, civil partnership, separated, 
divorced or widowed
Alcohol consumption Tick box—average units per week: 0, 1–5, 6–10, 11–15, 16–20, 21–40, >40
Impact of RA on work Work productivity question from WPAI-SHP
Postcode Free text for first half of postcode
Belief that sleep affects HRQoL 0–10 NRS: 0 ‘Not at all likely’, 10 ‘Very likely’
Information about RA
Date of RA diagnosis Month and year
Disease activity RAPID-3
Comorbid rheumatic disease(s) and 
sleep-related problem(s)
Check list—osteoarthritis, spondyloarthropathy/ankylosing spondylitis, fibromyalgia/
chronic widespread pain, gout or other crystal arthritis, Sjögren’s syndrome, restless 
leg syndrome, obstructive sleep apnoea/snoring, thyroid disorder, diabetes, multiple 
sclerosis, hypertension
Menopausal status Tick box—yes/no
Current medication(s) and non-
pharmacological intervention use
Check list—paracetamol, NSAIDs, other analgesics, weak opiates, strong opiates, 
drugs for neuropathic pain, glucocorticoids, synthetic DMARDs, biological DMARDs, 
sedatives (or hypnotics), mood stabilisers, antidepressants, other sleep medications
Free-text box
Health status information
Disease-specific quality of life AIMS2-SF
Generic Quality of Life WHOQOL-BREF
Prioritisation domains for good HRQoL Participants are asked to use a free text box to indicate top three things which are 
most important to them to ensure they have good quality of life
Sleep quality PSQI
Beliefs about sleep DBAS-16
Insomnia SCI
Mood HADS
Self-efficacy ASES-8
Cognitive flexibility CAQ-8
AIMS2-SF, Arthritis Impact Measurement Scale 2-Short Form; ASES-8, Arthritis Self-Efficacy Scale-8 item; CAQ-8, Committed Action 
Questionnaire; DBAS-16, Dysfunctional Beliefs and Attitudes about Sleep questionnaire; DMARDs, disease modifying antirheumatic drugs; 
HADS, Hospital Anxiety and Depression Scale; HRQoL, health-related quality of life; NRS, numerical rating scale; NSAIDs, non-steroidal anti-
inflammatory drugs; PSQI, Pittsburgh Sleep Quality Index; RA, rheumatoid arthritis; RAPID-3, Routine Assessment of Patient Index Data 3; 
SCI, Sleep Condition Indicator; WPAI-SHP, Work Productivity and Activity Impairment—specific health problem. 
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Medications
Participants will also be asked to record the use of medica-
tions including analgesics (eg, paracetamol, non-steroidal 
anti-inflammatories and opiates and DMARDs (eg, gluco-
corticoids, biological DMARDs). The use of sleep medica-
tions, including sedatives or hypnotics, mood stabilisers, 
antidepressants, other sleep medications (eg, chlorprom-
azine, haloperidol) will also be collected and participants 
will be given a free-text box to record other medications 
or coping strategies they use and the purpose for using 
the strategy (table 1).
Quality of life (QoL)
As is recommended,25 participants will complete a 
generic and disease specific measure of HRQoL. Generic 
HRQoL will be reported using the WHOQOL-BREF, 
a 26-item instrument which measures six domains in 
the past 14 days: overall perception of HRQoL (one 
discrete response item), health (one discrete response 
item), physical (seven discrete response items), psycho-
logical (six discrete response items), social relationships 
(three discrete response items) and environment (eight 
discrete response items). The items from each domain 
are summed and transformed into a 0–100 score, where 
higher scores indicate better HRQoL.26 The WHOQOL-
BREF has good internal consistency, discriminant validity 
(ie, discriminating ill vs well groups) and sensitivity to 
change.26
Disease-specific HRQoL will be reported using the 
26-item Arthritis Impact Measurement Scale 2-Short 
Form (AIMS2-SF). The AIMS2-SF uses discrete response 
items to capture five domains within a 4-week recall 
period: physical (13 items), symptom (3 items), affect (4 
items), social interaction (4 items) and role (2 items). 
After some items are reverse coded, domain items are 
summed and converted into a 0–10 scale, where higher 
scores indicate poorer HRQoL.27 The AIMS2-SF shows 
good internal consistency and acceptable construct 
validity. The scale also generally demonstrates prom-
ising evidence of sensitivity to change, but there is less 
evidence supporting this for social interaction and role 
subscales.27
Participants will also be asked to use a free text box to 
indicate the top three things which are most important to 
them to ensure they have good QoL.
Sleep quality and beliefs about sleep
Sleep quality in the past month will be measured using the 
Pittsburgh Sleep Quality Index (PSQI), the most widely 
used measure within clinical and research settings.28 
The 18-item instrument comprises seven domains: sleep 
quality (one discrete response item), sleep latency (one 
free-text item; one discrete response item), sleep dura-
tion (one free-text item), sleep efficiency (two free-text 
items), sleep disturbances (nine discrete response items), 
sleep medications (one discrete response item), daytime 
dysfunction (two discrete response items). The PSQI has 
good reliability and validity28 and demonstrates good 
sensitivity and specificity to distinguish good and poor 
sleepers.29
Participants will also record information regarding 
their beliefs about sleep using the 16-item Dysfunctional 
Beliefs and Attitudes about Sleep instrument (DBAS-
16). Beliefs about causes, consequences and treatment 
of sleep problems are rated on 11-point Likert scales 
ranging from 0 (strongly disagree) to 10 (strongly agree). 
Scores are summed and averaged to produce a mean item 
score where higher scores indicate stronger endorsement 
of maladaptive beliefs about sleep.30 The DBAS-16 has 
good internal consistency and test-retest reliability.30
Mood, self-efficacy and cognitive flexibility
Finally, mood, self-efficacy and cognitive flexibility will be 
measured as important covariates which may affect the 
relationship between sleep and HRQoL. Mood, specifi-
cally anxiety and depression, will be measured using the 
14-item Hospital Anxiety and Depression Scale (HADS).31 
Anxiety (seven items) and depression (seven items) in 
the preceding week are reported using discreet response 
questions, scored 0–3. Subscale items are summed to 
produce a score of 0–21, where higher scores represent 
poorer mood.31 Scores rend to be categorised as 0–7 
‘normal’, 8–10 ‘borderline’, >11 ‘caseness’. The HADs 
is well accepted and has strong internal consistency and 
high test-retest reliability.31
Self-efficacy will be assessed using the Arthritis Self-Ef-
ficacy Scale-8 item (ASES-8),32 which will record infor-
mation about participants’ self-efficacy for pain (2 0–10 
NRS), preventing pain and fatigue interference (2 0–10 
NRS) and for other symptoms (4 0–10 NRS). A self-ef-
ficacy score, ranging between 1 and 10, is produced by 
summing all items and calculating the mean value.32 
Higher scores indicate better self-efficacy. The ASES-8 
has been shown to have good reliability, validity and sensi-
tivity to change.32
Cognitive flexibility will be recorded using the 
Committed Action Questionnaire (CAQ-8), to assess 
participants’ abilities to persist with or change behaviour 
in relation to their present situation.33 The CAQ-8 
comprises four positive, and four negative, commitment 
to action subscales, which are recorded using 7-point 
Likert scales. An overall flexibility is scored by reverse 
coding the negative commitment subscales and summing 
all items, with higher scores indicating greater flexibility.33 
The CAQ-8 has been shown to have good reliability and 
internal consistency.33
Study commences (day 1)
On the agreed study start date, participants will receive 
a text message on the mobile phone number provided 
during the recruitment process. The reminder text 
message will ask participants to put on their activity 
monitor and to download the study app and register for 
an account. It will also include a study password, which 
will unlock the app to allow the participant to commence 
full registration and a reminder of their QUASARid, 
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which must be entered during the registration process 
to enable data linkage between the study app, actigraph 
watch and paper questionnaires.
App installation and account set-up
Instructions about how to download the study app, which 
can be installed onto the participants’ Apple or Android 
smartphone, tablet or both, will be included within the 
study pack that will be posted to participants. Once the 
app is installed participants will be asked to:
 ► complete a standard registration form (including 
creation of a username and password),
 ► enter their unique QUASARid, sex and date of birth, 
to enable linkage between the study’s different data 
collection platforms.
Registrations will be monitored via a live database, held 
by uMotif, of the data collected by the study app, to which 
the study team is provided secure access. All data provided 
by participants using the study app will be immediately 
transferred to uMotif server and visible in the database 
in real-time via 3G/4G/Wifi. Any participants who have 
not registered with the app on their agreed start date, or 
within a 5-day window of that date, will be contacted by 
the study team to understand what issues may have arisen. 
If appropriate, participation in the study may be resched-
uled for a later date.
Data collection
Following app-installation and the completion of the 
baseline questionnaire, participants will commence data 
collection lasting a total of 60 days. The first 30 days of 
the study comprise the continuous data collection phase 
of the study during which time participants wear the acti-
graph watch 24 hours a day and complete a sleep diary 
one time a day and symptom reports two times a day. 
During this 30-day monitoring period, participants will 
also complete follow-up questionnaires on days 10, 20 
and 30 of the study. No data are recorded between days 
31 and 59, but participants are asked to complete a final 
follow-up questionnaire on day 60 of the study.
During focus groups conducted to inform the design 
of this study, participants discussed a desire to have 
options for ongoing support from the study team via tele-
phone contact. For that reason, we will send personalised 
messages on days 5, 15 and 25 to encourage participation 
and give the participant the option to email or telephone 
the study team if they would like to discuss any issues or 
concerns. Any emails or requests for telephone calls will 
be responded to by the study’s postdoctoral research 
associate, or principal investigator, at the earliest possible 
opportunity and no later than one working day after the 
response is received.
A full outline of the data collected is provided below.
days 1–30—Actigraph watch and uMotif app
Continuous monitoring of sleep and physical activity
Participants will wear the MW8 (CamNtech) for 
24 hours a day over the 30 days of continuous data collec-
tion. The MW8 is a Class I Medical device which conforms 
to the essential safety and health requirements and provi-
sions of EC Council Directives 93/42.EEC, Annex VII. 
The MW8 requires a standard watch battery (CR2032) 
which is replaced each time the watch is used. The config-
uration of the MW8 for the present study will enable the 
watch to collect data for up to 45 days, providing an addi-
tional 2-week window for data to be collected in instances 
where study entry may have been delayed.
The MW8 monitors limb or bodily movements during 
daily living and sleep at 30 s time points (epochs) using a 
triaxial accelerometer. It is waterproof for up to 1 hour at 
1 m and is therefore suitable for use while swimming or 
showering. Participants are instructed to wear the MW8 
on their non-dominant wrist.
Actigraphy has been validated against polysomnography 
data.34 The MW8 has been shown to provides reliable esti-
mates for both sleep (including sleep latency, duration, 
Figure 2 Screenshot of uMotif study app.
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efficiency and fragmentation) and physical activity when 
worn for at least 14 days35–37 and has a number of practical 
features which make it suitable for the purposes of this 
study, including an event marker and prolonged battery 
life. Furthermore, the MW8 was specifically selected by 
participants invited to a research design focus group, who 
identified the MW8 as their preferred device due to the 
comfort of wearing it and the lightweight and unobtru-
sive design.
There is no real-time transmission of actigraphy data 
because the data are stored on the watches internal 
memory and can only be downloaded via a USB connec-
tion. It will therefore not be possible to assess participant 
compliance until after data collection has been completed 
and the actigraph watch is returned.
Following the receipt and download of actigraphy data 
the following variables will be extracted: total sleep time 
(the total time spent in sleep according to the epoch-by-
epoch wake/sleep categorisation), sleep onset latency 
(the time which elapsed between the participant getting 
into bed and the participant falling asleep) and sleep effi-
ciency (the total sleep time, expressed as a proportion 
of the total times pent in bed). The sleep fragmentation 
index, a measure of the degree of sleep discontinuity, will 
be calculated as a percentage of the total time categorised 
as mobile in the epoch-by-epoch mobile/immobile cate-
gorisation and the number of immobile bouts which were 
less than or equal to 1 min in length.
daily symptom reporting
During the 30-day continuous data collection, partici-
pants will be asked to use the uMotif study app to report 
their experience of daily symptoms. Within the app, the 
unique 'motif' interface is used by patients to simply track 
their daily symptoms. The motif which comprises 10 
symptom segments, such as pain severity as is highlighted 
in figure 2. The uMotif study app has been used in multiple 
ethics-approved studies, capturing over 64 million data 
points from patients using their own devices. The uMotif 
app has been specifically configured to capture the data 
required for the QUASAR study.
Participants will receive prompts two times a day to 
complete the symptom ratings, once in the morning and 
once in the afternoon/evening. Symptom data are scored 
on an ordinal scale of 1–5 and are recorded by touching 
and sliding the relevant segment within the motif. The 
symptoms to be recorded (table 2) were defined and 
agreed with consultation of participants in focus groups.38
Throughout the study, participants will receive 
reminders via the study app to complete the symptom 
assessments at 08:00 and 18:00 hours. Participants will be 
able to provide additional symptom reports throughout 
the day at their discretion.
The completion of these symptom data can be contin-
ually monitored via a live database, held by uMotif, of the 
data collected by the study app, to which the study team 
is provided secure access. As all data provided by partic-
ipants using the study app are immediately transferred 
to uMotif server in real-time via 3G/4G/Wifi, it will be 
possible for the study team to produce daily reports to 
monitor whether participants are completing their data 
in line with the study protocol.
A window of two consecutive days during the 30-day 
continuous monitoring period will be considered an 
acceptable period of non-completion for the daily 
symptom reports, sleep diaries and follow-up question-
naires. After this point, participants will receive a single 
reminder text message to encourage them to recom-
mence data entry or contact the study team to discuss any 
concerns or issues, as appropriate.
Days 2–31 —Consensus Sleep Diary
The reminder sent to participants at 8am will also ask them 
to complete the 9-item Consensus Sleep Diary (CSD). 
This diary, which is completed in a separate section of 
the study app (figure 3), pertains to the previous night’s 
sleep. To ensure coverage of all 30 nights of actigraphy 
data collection, it will be completed on the morning of 
Table 2 Daily symptoms to be captured by the uMotif study app
Symptom Question
Anchor 1 (centre of 
motif)
Anchor 5 (outside of 
motif)
Pain How severe is your pain? No pain Very severe pain
Fatigue How severe is your fatigue? No fatigue Very severe fatigue
Mood How is your mood? Depressed Very happy
Well-being How well do you feel? Very well Very unwell
Anxiety How anxious do you feel? Very well Very anxious
Illness impact How much is your illness impacting on your 
activities?
No impact Very severe impact
Disease control How much control do you feel you have over your 
symptoms?
No control Very good control
Challenge How challenging are you finding today? Not challenging Severely challenging
Sleepiness How sleepy do you feel? Not sleepy Very sleepy
Concentration How would you rate your concentration? Poor Excellent
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days 2–31. Participants will receive an automatically gener-
ated reminder every morning at 08:00 hours to complete 
the CSD, but are able to complete the diary earlier if they 
wish.
The 9-item CSD asks participants to record the time they 
got into bed, when they tried to sleep, how long it took to 
fall asleep, number and duration of night time awaken-
ings, the time of final awakening, when they got out of bed, 
sleep quality and how refreshed they felt on awakening. 
The CSD is widely considered to be a gold-standard sleep 
diary, having been developed through the collaboration 
of sleep experts and potential users.39 40 An additional 
four items will ask participants to report the duration of 
morning stiffness (in min), emotional strength, motiva-
tion and worry about sleeping the previous evening.
As with the symptom reports, it will be possible to 
continually monitor sleep diary completion using the live 
database, held by uMotif. The study team will therefore 
produce daily reports to monitor whether participants 
are completing their sleep diaries in line with the study 
protocol. Any participant who does not complete their 
sleep diary for more than 2 days will receive a single 
reminder text message to encourage them to recom-
mence data entry or contact the study team to discuss any 
concerns or issues, as appropriate. It will not be possible 
to retrospectively complete the sleep diaries for missing 
days.
Days 10, 20 and 30—HRQoL, disease activity and life events
A number of follow-up questionnaires will be used 
throughout the study(table 3). Prompts to complete 
the questionnaires will be sent. Requests to complete 
the follow-up questionnaires will be delivered to partic-
ipants, via the app to participants, on the day they are 
to be completed when they open the study app. These 
reminders will be automatically generated and sent from 
uMotif and cannot be personalised. The questionnaires 
completed at days 10, 20 and 30 will capture the below 
items:
 ► Disease-specific QoL—AIMS2-SF.
 ► Generic QoL—WHOQOL-BREF.
 ► Disease activity—RAPID-3.
 ► Occurrence of important events.
As with all data collected via the study app, the data 
recorded in each follow-up questionnaire will be imme-
diately transferred to uMotif server in real-time via 
3G/4G/Wifi. Completion of follow-up questionnaires 
will be monitored within daily reports produced by the 
study team and any participant who has not completed 
their questionnaire within 2 days of the required date 
will receive a single reminder text message to request 
that they complete the questionnaire as soon as possible. 
Participants will be given instructions to manually access 
and complete the follow-up questionnaire forms or 
contact the study team to discuss any concerns or issues, 
as appropriate.
Following the 30 days of data collection, participants 
will receive a text message to remind them to stop wearing 
the activity monitor and to send it back to the study team 
at the earliest convenient time, using the provided return 
addressed envelope. The envelopes, to which the rele-
vant postage will be attached to return the package using 
Royal Mail Signed For 1st Class must be returned via the 
local post office to obtain proof of postage; participants 
will not be required to pay any additional postage to 
obtain this. In instances where the watch does not appear 
to have been dropped off at the Post Office within 5 days 
of the expected end date, the study team will contact the 
participant.
Participants are not expected to continue tracking their 
symptoms or using the study app for continuous moni-
toring after day 30 and at this point participants may wish to 
uninstall the study app. For that reason, as the completion 
of the study’s final questionnaire will occur 30 days after 
the continuous data collection phase has ended (day 60), 
participants may no longer be using the app and may have 
Figure 3 Screenshot of consensus sleep diary within study 
app.
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uninstalled it from their devices. Within the text message 
sent on day 30 of the study to congratulate participants on 
completing the continuous monitoring phase, participants 
will be asked to advise the study team if they would like to 
receive a paper copy of the final follow-up questionnaire.
Day 60—final follow-up questionnaire
The study’s final follow-up questionnaire will be completed 
at day 60. It is assumed that those who do not request a 
paper copy will be happy to complete the questionnaire 
using the app. Participants will be prompted to complete 
the questionnaire by reminders automatically generated 
and sent from uMotif. As before these reminders are 
generic and cannot be personalised.
The questionnaire will capture:
 ► Disease-specific QoL—AIMS2-SF.
 ► Generic QoL—WHOQOL-BREF.
 ► Prioritisation of domains—participants asked to use 
a free text box to indicate the top three things which 
are most important to them to ensure they have good 
QoL.
 ► Disease activity—RAPID-3.
 ► Current medication(s) and non-pharmacological 
intervention use.
 ► Sleep quality—PSQI.
 ► Occurrence of important events.
A complete overview of data collection and participant 
contact is shown in figure 4.
Sample size
Following published guidance,41 42 a sample size calcula-
tion has been conducted to determine a minimum sample 
size required to enable the study to conduct structural 
equation modelling (SEM). We have based estimated the 
sample size to detect a conservative minimum effect size 
(defined as correlations between pairs of latent variables) 
of 0.2 (rated as small). Based on our hypothesised model 
using baseline and 60-day measurements, containing 13 
observed variables and four latent variables, with a signif-
icance level of 5% and power of 80%, a minimum sample 
size of 166 participants is required. Recommended sample 
sizes for latent growth curve analyses are defined in rela-
tion to the number of participants and the number of 
repeated observations and suggest a minimum number of 
100 participants should complete at least 3 data points.43 
Our minimum sample size required and data collection 
protocol are therefore in excess of the requirements for 
latent growth curve analyses. In this study, 50 actigraph 
watches will be obtained. This means that the maximum 
capacity for concurrent data collection is 50 and that data 
collection will be conducted in waves.
Using data from previous studies, we conservatively 
estimate that: a total of 3500 questionnaires mailed will 
provide 1750 (50%) returned and completed screening 
questionnaires, 350 (20%) will agree to take part and 175 
(50%) will provide complete useable data, in excess of 
the minimum 166 persons required for the analysis. It is 
important that a representative sample of people with RA 
is enrolled into the study. However, data regarding the 
characteristics (eg, age and sex) of persons who receive 
information about the study will not be available through 
the proposed recruitment channels. The presence of 
sampling bias will be examined for by comparing the age 
and sex distribution of UK population data (table 4) to 
Table 3 Summary of data collection via study questionnaires
Preregistration
Day
≤1
(paper)
Day
10
(app)
Day
20
(app)
Day
30
(app)
Day
60
(app/paper)
Screening questionnaire X
Demographics X
Information about RA X
RAPID-3 X X X X X
Current medication(s) and non-
pharmacological intervention use
X X
AIMS2-SF X X X X X
WHOQOL-BREF X X X X X
PSQI X X
DBAS-16 X
SCI X
HADS X
ASES-8 X
CAQ-8 X
AIMS2-SF, Arthritis Impact Measurement Scale 2-Short Form; ASES-8, Arthritis Self-Efficacy Scale-8 item; CAQ-8, Committed Action 
Questionnaire; DBAS-16, Dysfunctional Beliefs and Attitudes about Sleep questionnaire; HADS, Hospital Anxiety and Depression Scale; 
PSQI, Pittsburgh Sleep Quality Index; RA, rheumatoid arthritis; RAPID-3, Routine Assessment of Patient Index Data 3; SCI, Sleep Condition 
Indicator. 
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(1) persons who complete and return screening question-
naires and (2) recruited participants to available.
Recruitment
In order to manage the flow of participants into the study 
and given the limited number of actigraph watches avail-
able, NRAS have agreed to contact mailing list members 
in seven regionally stratified recruitment waves in order 
that actigraph watches can be returned by earlier partic-
ipants, prepared and sent out to future participants. The 
dates of each wave are listed below:
Wave 1—8 May 2017
Wave 2—17 July 2017
Wave 3—25 September 2017
Wave 4—4 December 2017
Wave 5—12 February 2018
Wave 6—23 April 2018
Wave 7—2 July 2018
The identification of GP practices and NHS Rheuma-
tology clinics able to support recruitment to the QUASAR 
study will occur throughout the study. Once identified, 
the letters sent to potential participants identified via 
the screening of GP records will be sent to coincide with 
the above mailing waves used by NRAS. Participants who 
see information about the study in NHS Rheumatology 
clinics will be free to contact the study team at any point, 
however their enrolment into the study will be restricted 
to coincide with the above mailing waves.
Targeted recruitment
The study’s third objective is to examine whether the rela-
tionships between sleep and HRQoL are moderated by 
age and sex. It is therefore important to ensure that a 
representative sample of people with RA are enrolled into 
Table 4 The prevalence of rheumatoid arthritis in UK
 Age Males (%) UK estimate Females (%) UK estimate
16–44 0.02 2500 0.12 15 100
45–64 0.58 42 900 1.67 126 900
65–74 1.14 27 100 2.56 67 800
75+ 2.18 39 100 2.99 85 700
Total adult population 0.44 106 500 1.16 297 600
Figure 4 Data collection and participant contact across 60 days for participants enrolled in QUASAR. AIMS2-SF, 
Arthritis Impact Measurement Scale 2-Short Form; ASES-8, Arthritis Self-Efficacy Scale-8 item; CAQ-8, Committed Action 
Questionnaire; DBAS-16, Dysfunctional Beliefs and Attitudes about Sleep questionnaire; HADS, Hospital Anxiety and 
Depression Scale; PSQI, Pittsburgh Sleep Quality Index; QoL, Quality of Life; QUASAR, quality of life, sleep and rheumatoid 
arthritis; RA, rheumatoid arthritis; RAPID-3, Routine Assessment of Patient Index Data 3; SCI, Sleep Condition Indicator. 
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the study. Table 4 displays the estimated UK prevalence of 
RA and demonstrates that women are around three times 
more likely to be affected than men and the increased 
prevalence of RA in older populations.2
From previous studies, we know that young men44 and 
older people of both sexes are often under-represented 
populations.41 42 They may be less likely to express an 
interest in taking part in studies41 or they may be excluded 
by the inclusion/exclusion criteria used.42 In anticipa-
tion that some of these ‘hard to reach’ groups may be 
under-represented in our sample, we propose to monitor 
the characteristics of participants who are enrolled in the 
study and apply stratified recruitment processes in later 
recruitment waves if required.
data analysis plan
Analyses techniques used in descriptive epidemiology 
will address aim 1. Data will be presented as absolute 
numbers and percentages, presented for the whole group 
and stratified by age (18-44; 45-64; 65-74; 75+), sex and 
level of socioeconomic deprivation (Index of Multiple 
Deprivation,45 derived using participant postcodes and 
categorised as quartiles of most deprived, deprived, less 
deprived and least deprived).
Using SEM and latent trajectory models (LTM), we will 
address the study’s second aim: to examine if disrupted 
sleep patterns are associated with poor HRQoL.
SEM will assess whether the sleep and sleep/wake 
rhythm-associated parameters measured at baseline 
mediate the association between RAPID-3 score and 
HRQoL at 60 days (the end of the follow-up period) 
allowing intercorrelation between the sleep and sleep/
wake rhythm-associated parameters and adjusting for 
putative confounders. The SEM analysis will be repeated 
adding to the model pain, fatigue and mood to assess the 
effect of on HRQoL (eg, figure 5). Finally, the analysis will 
be repeated including the data on mediators collected at 
day 30. This will allow assessment of whether RAPID-3 
predicts change in the mediating factors and the subse-
quent impact on HRQoL at day 60. An exploratory multi-
group SEM analysis will assess the moderating effects of 
age and sex and will thus address the third aim of this 
study.
Figure 5 Hypothetical model of the pathways of relationship between rheumatoid arthritis and quality of life disease severity, 
sleep, fatigue, mood and pain—simple model. In this figure, rectangles represent observed variables and circles represent 
the constructs those variables represent. Solid arrows represent the pathways to be tested. AIMS2-SF, Arthritis Impact 
Measurement Scale 2-Short Form; CSD, Consensus Sleep Diary; PSQI, Pittsburgh Sleep Quality Index; RAPID-3, Routine 
Assessment of Patient Index Data 3. 
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The SEM analysis assumes that the identified associ-
ations are consistent across participants and use only 
selected time points. LTM will use all of the repeated 
measures data to fully explore the longitudinal rela-
tionships between RAPID-3, mediators and HRQoL and 
their variation between participants. First, multilevel 
growth models, accounting for the clustering of repeated 
measures (level 1) within participants (level 2), will assess 
the prospective associations of RAPID-3 with key observed 
pathways from the SEM analysis and the prospective asso-
ciations with HRQoL. Second, we will assess if distinct 
clusters of participants can be identified with different 
longitudinal courses using dual trajectory latent class 
growth analysis. We will assess how these trajectories are 
associated with change in HRQoL over 60 days and the 
sociodemographic and clinical characteristics associated 
with these different trajectories.
Finally, causal mediation analysis methods, specifically 
the mediational g-formula, will be used to estimate how 
successful treatments that improve sleep might be for 
people with RA. G-formula will be applied to the SEM 
models outlined above. This analysis will estimate the 
potential effect of a hypothetical intervention targeted at 
the key causal pathways between the observed variables 
and HRQoL. The hypothetical interventions which most 
improve HRQoL will indicate the best treatment targets 
to be tested in future intervention studies. For example, if 
disrupted circadian pathways were found to be important 
drivers of poor QoL, a future study might investigate 
the impact of advancing or delaying them using photo-
therapy.46 However, it is likely that multiple pathways (eg, 
sleep-wake cycle; sleep-wake cycle and pain) will impact 
on HRQoL and an intervention ‘package’ (eg, photo-
therapy and behavioural therapy47) will need to be devel-
oped based on those pathways.
EthICs And dIssEMInAtIon
This study underwent a full NHS Research Ethics 
Committee (REC) review and was allocated to the 
National Research Ethics Service (NRES) Committee 
North West—Liverpool Central REC. 
Results from this study will be disseminated at regional 
and international conferences and in peer-reviewed 
journals. Results will also be disseminated at Patient and 
Public Engagement events where opportunities arise and 
are appropriate.
dIsCussIon
People with RA frequently report reduced HRQoL, 
which may be caused by sleep disturbances. Few studies 
have determined the relationship between sleep and 
QoL among RA populations and those which have are 
laden with methodological challenges, which preclude 
accurate assessment and understanding of the relation-
ship between sleep and HRQoL. The QUASAR study 
is a comprehensive study which has been designed to 
overcome these challenges. The results of this study will 
inform future intervention studies by answering key ques-
tions regarding the link between sleep and poor HRQoL.
Contributors JM led the conception and design of the study. All authors made 
substantial contributions to the conception and design of the study. JM and ML 
planned the statistical analysis. KLD wrote the first draft of the protocol manuscript. 
LC, VS, SM, BH, BJ, ML, SDK, WGD and JM critically reviewed the protocol 
manuscript. All authors approved the final version of the document.
Funding This study is supported by Arthritis Research UK grant number 21188. 
The study is also supported by infrastructure support from the Arthritis Research UK 
Centre for Epidemiology (grant reference 20380). 
Competing interests None declared.
patient consent Not required.
Ethics approval National Research Ethics Service (NRES) Committee North 
West—Liverpool Central REC (reference 17/NW/0217).
provenance and peer review Not commissioned; externally peer reviewed.
data sharing statement We intend to make data available for data sharing after 
the data collection has been completed and the primary aims of the study are met. 
open Access This is an Open Access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited and the use is non-commercial. See: http:// creativecommons. org/ 
licenses/ by- nc/ 4. 0/
© Article author(s) (or their employer(s) unless otherwise stated in the text of the 
article) 2018. All rights reserved. No commercial use is permitted unless otherwise 
expressly granted.
rEFErEnCEs
 1. NICE. Rheumatoid arthritis: national clinical guideline for 
management and treatment in adults. Clinical guideline [CG79]: 
National Institute of Health and Clinical Excellence, 2015.
 2. Symmons D, Turner G, Webb R, et al. The prevalence of rheumatoid 
arthritis in the United Kingdom: new estimates for a new century. 
Rheumatology 2002;41:793–800.
 3. Verstappen SM, Bijlsma JW, Verkleij H, et al. Overview of 
work disability in rheumatoid arthritis patients as observed 
in cross-sectional and longitudinal surveys. Arthritis Rheum 
2004;51:488–97.
 4. Dominick KL, Ahern FM, Gold CH, et al. Health-related quality of 
life among older adults with arthritis. Health Qual Life Outcomes 
2004;2:5.
 5. Gerhold K, Richter A, Schneider M, et al. Health-related quality 
of life in patients with long-standing rheumatoid arthritis in the 
era of biologics: data from the German biologics register RABBIT. 
Rheumatology 2015;54:1858–66.
 6. Geryk LL, Carpenter DM, Blalock SJ, et al. The impact of co-
morbidity on health-related quality of life in rheumatoid arthritis and 
osteoarthritis patients. Clin Exp Rheumatol 2015;33:366–74.
 7. Drewes AM, Svendsen L, Taagholt SJ, et al. Sleep in rheumatoid 
arthritis: a comparison with healthy subjects and studies of sleep/
wake interactions. Br J Rheumatol 1998;37:71–81.
 8. Roehrs T, Diederichs C, Gillis M, et al. Nocturnal sleep, daytime 
sleepiness and fatigue in fibromyalgia patients compared to 
rheumatoid arthritis patients and healthy controls: a preliminary 
study. Sleep Med 2013;14:109–15.
 9. Crosby LJ. Factors which contribute to fatigue associated with 
rheumatoid arthritis. J Adv Nurs 1991;16:974–81.
 10. Wolfe F, Walitt BT, Katz RS, et al. Symptoms, the nature of 
fibromyalgia, and diagnostic and statistical manual 5 (DSM-5) 
defined mental illness in patients with rheumatoid arthritis and 
fibromyalgia. PLoS One 2014;9:e88740.
 11. Lee YC, Chibnik LB, Lu B, et al. The relationship between disease 
activity, sleep, psychiatric distress and pain sensitivity in rheumatoid 
arthritis: a cross-sectional study. Arthritis Res Ther 2009;11:1–11.
 12. Lautenbacher S, Kundermann B, Krieg JC. Sleep deprivation and 
pain perception. Sleep Med Rev 2006;10:357–69.
 13. Goodchild CE, Treharne GJ, Booth DA, et al. Daytime patterning 
of fatigue and its associations with the previous night's discomfort 
14 Druce KL, et al. BMJ Open 2018;8:e018752. doi:10.1136/bmjopen-2017-018752
Open Access 
and poor sleep among women with primary Sjögren's syndrome or 
rheumatoid arthritis. Musculoskeletal Care 2010;8:107–17.
 14. Irwin MR, Olmstead R, Carrillo C, et al. Sleep loss exacerbates 
fatigue, depression, and pain in rheumatoid arthritis. Sleep 
2012;35:537–43.
 15. Sariyildiz MA, Batmaz I, Bozkurt M, et al. Sleep quality in 
rheumatoid arthritis: relationship between the disease severity, 
depression, functional status and the quality of life. J Clin Med Res 
2014;6:44–52.
 16. Purabdollah M, Lakdizaji S, Rahmani A, et al. Relationship between 
sleep disorders, pain and quality of life in patients with rheumatoid 
arthritis. J Caring Sci 2015;4:233–41.
 17. Goes ACJ, Reis LAB, Silva MBG, et al. Rheumatoid arthritis and 
sleep quality. Revista Brasileira de Reumatologia 2017;57:294–8.
 18. Guo G, Fu T, Yin R, et al. Sleep quality in Chinese patients with 
rheumatoid arthritis: contributing factors and effects on health-
related quality of life. Health Qual Life Outcomes 2016;14:151.
 19. Tafti M. Genetic aspects of normal and disturbed sleep. Sleep Med 
2009;10:S17–21.
 20. Buysse DJ, Ancoli-Israel S, Edinger JD, et al. Recommendations 
for a standard research assessment of insomnia. Sleep 
2006;29:1155–73.
 21. Buysse DJ. Sleep health: can we define it? Does it matter? Sleep 
2014;37:9–17.
 22. Muller S, Hider SL, Raza K, et al. An algorithm to identify rheumatoid 
arthritis in primary care: a Clinical Practice Research Datalink study. 
BMJ Open 2015;5:e009309.
 23. Anderson J, Caplan L, Yazdany J, et al. Rheumatoid arthritis 
disease activity measures: American College of Rheumatology 
recommendations for use in clinical practice. Arthritis Care Res 
2012;64:640–7.
 24. Espie CA, Kyle SD, Hames P, et al. The sleep condition indicator: 
a clinical screening tool to evaluate insomnia disorder. BMJ Open 
2014;4:e004183.
 25. Scott DL, Garrood T. Quality of life measures: use and abuse. 
Baillieres Best Pract Res Clin Rheumatol 2000;14:663–87.
 26. World Health Organisation. Programme on mental health: WHOQOL 
user manual, 2012.
 27. Gignac MA, Cao X, Mcalpine J, et al. Measures of disability: 
Arthritis Impact Measurement Scales 2 (AIMS2), Arthritis Impact 
Measurement Scales 2-Short Form (AIMS2-SF), The Organization 
for Economic Cooperation and Development (OECD) Long-Term 
Disability (LTD) Questionnaire, EQ-5D, World Health Organization 
Disability Assessment Schedule II (WHODASII), Late-Life Function 
and Disability Instrument (LLFDI), and Late-Life Function and 
Disability Instrument-Abbreviated Version (LLFDI-Abbreviated). 
Arthritis Care Res 2011;63(Suppl 11):S308–4.
 28. Mollayeva T, Thurairajah P, Burton K, et al. The Pittsburgh sleep 
quality index as a screening tool for sleep dysfunction in clinical and 
non-clinical samples: A systematic review and meta-analysis. Sleep 
Med Rev 2016;25:52–73.
 29. Buysse DJ, Reynolds CF, Monk TH, et al. The pittsburgh sleep 
quality index: a new instrument for psychiatric practice and research. 
Psychiatry Res 1989;28:193–213.
 30. Morin CM, Vallières A, Ivers H. Dysfunctional beliefs and attitudes 
about sleep (DBAS): validation of a brief version (DBAS-16). Sleep 
2007;30:1547–4.
 31. Herrmann C. International experiences with the Hospital Anxiety and 
Depression Scale--a review of validation data and clinical results.  
J Psychosom Res 1997;42:17–41.
 32. Brady TJ. Measures of self-efficacy: Arthritis Self-Efficacy Scale 
(ASES), Arthritis Self-Efficacy Scale-8 Item (ASES-8), Children's 
Arthritis Self-Efficacy Scale (CASE), Chronic Disease Self-Efficacy 
Scale (CDSES), Parent's Arthritis Self-Efficacy Scale (PASE), and 
Rheumatoid Arthritis Self-Efficacy Scale (RASE). Arthritis Care Res 
2011;63(Suppl 11):S473–S485.
 33. McCracken LM, Chilcot J, Norton S. Further development in the 
assessment of psychological flexibility: a shortened Committed 
Action Questionnaire (CAQ-8). Eur J Pain 2015;19:677–85.
 34. Sadaka Y, Sadeh A, Bradbury L, et al. Validation of actigraphy with 
continuous video-electroencephalography in children with epilepsy. 
Sleep Med 2014;15:1075–81.
 35. Falck RS, Landry GJ, Brazendale K, et al. Measuring physical activity 
in older adults using motionwatch 8 actigraphy: how many days are 
needed? J Aging Phys Act 2017;25:51–7.
 36. Landry GJ, Best JR, Liu-Ambrose T. Measuring sleep quality in older 
adults: a comparison using subjective and objective methods. Front 
Aging Neurosci 2015;7:166.
 37. Elbaz M, Yauy K, Metlaine A, et al. Validation of a new actigraph 
motion watch versus polysomnography on 70 healthy and suspected 
sleep-disordered subjects. J Sleep Res 2012;21(Suppl 1):218.
 38. Short V, McBeth J, Druce KL, et al. Fluctuating, unpredictable and 
challenging: how pain, fatigue and sleep disturbance impact on 
quality of life in people with rheumatoid arthritis. Ann Rheumatic Dis 
2017;76.
 39. Maich KHG, Lachowski AM, Carney CE. Psychometric properties of 
the consensus sleep diary in those with Insomnia disorder. Behav 
Sleep Med 2018;16:1–18.
 40. Carney CE, Buysse DJ, Ancoli-Israel S, et al. The consensus sleep 
diary: standardizing prospective sleep self-monitoring. Sleep 
2012;35:287–302.
 41. Christopher Westland J, Westland JC. Lower bounds on sample 
size in structural equation modeling. Electron Commer Res Appl 
2010;9:476–87.
 42. Soper DS. A-priori sample size calculator for structural equation 
models (Online Software). version 4.0. 2012.
 43. Curran PJ, Obeidat K, Losardo D. Twelve frequently asked questions 
about growth curve modeling. J Cogn Dev 2010;11:121–36.
 44. Druce KL, McBeth J, van der Veer SN, et al. Recruitment and 
ongoing engagement in a UK smartphone study examining the 
association between weather and pain: cohort study. JMIR Mhealth 
Uhealth 2017;5:e168.
 45. Department of the Envrionment, Transport and the regions. Indices of 
deprivation 2000, 2000.
 46. Dodson ER, Zee PC. Therapeutics for circadian rhythm sleep 
disorders. Sleep Med Clin 2010;5:701–15.
 47. Ashburn MA, Staats PS. Management of chronic pain. The Lancet 
1999;353:1865–9.
